Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial
Authors
Harman Dhatt
Jonathan J. Hubbard (ORCID: https://orcid.org/0000-0002-5740-7325)
Sophia G. Liva (ORCID: https://orcid.org/0000-0002-3838-5001)
Kathy L. Sivils
Li He (ORCID: https://orcid.org/0000-0003-1016-9451)
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial
Harman Dhatt, Jonathan J. Hubbard, Sophia G. Liva, Kathy L. Sivils et al.
Citations
8 citations
Journal
The Lancet
Topics
Salivary Gland Disorders and Functions
Field-Weighted Citation Impact (FWCI)
9.31
article
Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial
Harman Dhatt, Jonathan J. Hubbard, Sophia G. Liva, Kathy L. Sivils, Li He, Ghaith Noaiseh, Steven Leonardo, Jocelyn H. Leu, Jada Idokogi, Kim Campbell, Keying Ma, Jacques-Éric Gottenberg, Kim Hung Lo
article en
8 citations
Abstract
No abstract available for this paper.
Publication Tag
The LancetVol. 406(10518)
Institutions
Centre National de la Recherche Scientifique (FR), Johnson & Johnson (United States) (US), University of Kansas Medical Center (US), Université de Strasbourg (FR)